Skip to main content
TipRanks
Go Ultimate75% OFF

aXichem AB Class A (A6X) Stock Price & Analysis

0 Followers

A6X Stock Chart & Stats

€0.12€0.01(8.41%)
At close: 5:30 PM GMT+1
€0.25€0.5€0.75€1Mar 3Oct 24Jul 17May 22Oct 12
Day’s Range
EUR 0.11 - EUR 0.12
52-Week Range
EUR 0.07 - EUR 0.29
Previous Close
EUR 0.11
Volume
N/A
Average Volume (3M)
50
Market Cap
EUR 11.24M
Enterprise Value
EUR 109.16M
Total Cash (Recent Filing)
EUR 2.87M
Total Debt (Recent Filing)
EUR 595.00K
Price to Earnings (P/E)
―
Beta
-0.20
Next Earnings
Nov 26, 2026 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very modest debt relative to equity reduces near-term solvency pressure and interest burden. This gives aXichem greater financial flexibility than a highly leveraged business, allowing more capacity to pursue regulatory, research, and commercialization activities while losses persist.

Patent-Based Product Platform

A patented phenylcapsaicin platform can support differentiated products and protect intellectual property across animal nutrition and other biological or industrial uses. Multiple potential applications create avenues for licensing, partnerships, and broader commercialization over the next several quarters.

Partner-Led Commercial Model

Using partners and distributors gives aXichem an established route to commercial markets without relying on large-scale in-house manufacturing. This model can help the company focus capital and personnel on R&D, intellectual property, regulatory work, and product adoption.

Bears Say

Revenue Decline And Volatility

The recent revenue contraction and volatile multi-year sales record indicate that commercial demand has not yet become dependable. Continued top-line instability can restrict operating leverage, weaken planning visibility, and make it harder to fund regulatory and product expansion internally.

Deep And Persistent Losses

Negative gross profit and an approximately 95% net margin loss show that the current business model is far from sustainable profitability. Unless pricing, sales scale, or cost economics improve materially, future growth may continue to consume capital rather than build durable earnings.

Recurring Cash Burn

Persistent operating and free-cash-flow deficits reduce financial resilience even though leverage is low. Ongoing cash consumption can require external funding if performance does not improve, potentially limiting strategic flexibility and exposing the company to dilution or financing dependence.

A6X FAQ

What was aXichem AB Class A’s price range in the past 12 months?
aXichem AB Class A lowest stock price was €0.07 and its highest was €0.29 in the past 12 months.
What is aXichem AB Class A’s market cap?
aXichem AB Class A’s market cap is €11.24M.
When is aXichem AB Class A’s upcoming earnings report date?
aXichem AB Class A’s next earnings report is estimated for Nov 26, 2026 (not yet confirmed), which is in 9 days.
How were aXichem AB Class A’s earnings last quarter?
aXichem AB Class A released its earnings results on Aug 27, 2026. The company reported -€0.018 earnings per share for the quarter, missing the consensus estimate of -€0.013 by -€0.005.
Is aXichem AB Class A overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does aXichem AB Class A pay dividends?
aXichem AB Class A does not currently pay dividends.
What is aXichem AB Class A’s EPS estimate?
aXichem AB Class A’s EPS estimate is -0.01.
How many shares outstanding does aXichem AB Class A have?
aXichem AB Class A has 76,343,340 shares outstanding.
What happened to aXichem AB Class A’s price movement after its last earnings report?
aXichem AB Class A reported an EPS of -€0.018 in its last earnings report, missing expectations of -€0.013. Following the earnings report the stock price went up 2.538%.
Which hedge fund is a major shareholder of aXichem AB Class A?
Currently, no hedge funds are holding shares in DE:A6X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology